Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.15
+4.6%
$1.75
$0.60
$3.08
$174.34M1.4394,228 shs87,295 shs
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$26.98
$26.96
$7.67
$27.06
$2.62B2.171.17 million shs2.26 million shs
Omeros Corporation stock logo
OMER
Omeros
$3.65
+5.4%
$3.73
$2.95
$13.60
$214.44M2.16733,974 shs427,243 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.35
-1.1%
$1.32
$1.21
$2.04
$1.07B1.343.87 million shs246,274 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-11.26%-8.07%-22.35%+207.81%+35.76%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
+2.37%+8.09%-10.82%-48.59%-14.57%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.45%+1.12%-1.45%-3.89%+3.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.9829 of 5 stars
3.73.00.00.02.51.70.6
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
3.2861 of 5 stars
3.40.00.04.40.01.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.6588 of 5 stars
3.52.00.04.42.85.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00179.72% Upside
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00393.69% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.75104.46% Upside

Current Analyst Ratings Breakdown

Latest OPK, OMER, CNTTF, MYOV, and IMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M45.03N/AN/A$2.47 per share0.87
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$230.97M11.36N/AN/A($5.04) per share-5.35
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.50$0.07 per share20.06$2.00 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/A
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)

Latest OPK, OMER, CNTTF, MYOV, and IMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/A
1.57
1.45
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28

Institutional Ownership

CompanyInstitutional Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
30.62%
Omeros Corporation stock logo
OMER
Omeros
48.79%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
1.90%
Omeros Corporation stock logo
OMER
Omeros
12.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
40797.24 million95.39 millionNot Optionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.14 +0.10 (+4.63%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Myovant Sciences stock logo

Myovant Sciences NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Omeros stock logo

Omeros NASDAQ:OMER

$3.65 +0.19 (+5.38%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.34 -0.02 (-1.10%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.